| 摘要 |
Giardia lamblia is the giardiasis causing agent, a worldwide intestinal disease which mainly affects children and immunocompromised population. The current treatments use drugs from the nitroimidazole group, which generate side effects, and also existing Giardia strains resistant to such drugs. Said situation has generated the search of novel strategies for developing improved antigiardals. Our team selected the tactic of using enzymes of the glycolytic pathway of the parasite as potential targets for designing the antigiardals, since Giardia obtains the energy thereof through the glucose metabolism, thereby being an essential pathway for surviving. Particularly, the Triose-phosphate isomerase of the Giardia (GITIM) was characterised, thus showing that is an effective target for designing antigiardals. Recently was identified that omeprazole, a drug widely used against gastritis and gastric ulcers, may be effectively applied as antigiardal. Omeprazole is specifically bonded to GITIM, thus being inactivated in a total manner. Omeprazole does not affect the homologue human enzyme; however it was effective in totally inhibiting the growth of Giardia in axenic cultures. It is proposed to generate a novel patent for using omeprazole and the stereoisomers as highly specific antigiardials.
|
